The PiP Study will assess the efficacy of HN001 supplementation from 14 to 16 weeks gestation in the prevention of GDM, BV, and vaginal GBS colonisation in pregnant women, and development of eczema and atopic sensitisation in their infants at one year and maternal depression and anxiety at 1–2 months postpartum. This evidence concerns the gene PIP and bacterial vaginosis.